Zhihong Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhihong Li has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Ding Liu
Department of Orthopaedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
2 shared publications- Tang Liu
Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, China
2 shared publications - Xianghong Zhang
Department of Orthopedics, the Second Xiangya Hospital of Central South University, 139# Middle Renmin Road, Changsha, Hunan, 410011, PR China.
2 shared publications Dou Bo
Clinical Medicine for Eight-Year-Program, Xiangya School of Medicine, Central South University, Changsha, Hunan, China
1 shared publicationLile He
Department of Orthopedics, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
1 shared publicationLiu Congwei
Department of Orthopaedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
1 shared publication
Latest Publications
- Open Access
- 18 September 2019
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 19 (1) , 1-8
Bacterial resistance trends among intraoperative bone culture of chronic osteomyelitis in an affiliated hospital of South China for twelve years
Background: The purpose of this study was to gather temporal trends on bacteria epidemiology and resistance of intraoperative bone culture from chronic ostemyelitis at an affiliated hospital in South China. Method: Records of patients with chronic osteomyelitis from 2003 to 2014 were retrospectively reviewed. The medical data were extracted using a unified protocol. Antimicrobial susceptibility testing was carried out by means of a unified protocol using the Kirby-Bauer method, results were analyzed according to Clinical and Laboratory Standards Institute definitions. Result: Four hundred eighteen cases met our inclusion criteria. For pathogen distribution, the top five strains were Staphylococcus aureus (27.9%); Pseudomonas aeruginosa (12.1%); Enterobacter cloacae (9.5%); Acinetobacter baumanii (9.0%) and Escherichia coli (7.8%). Bacterial culture positive rate was decreased significantly among different year-groups. Mutiple bacterial infection rate was 28.1%. One strain of Staphylococcus aureus was resistant to linezolid and vancomycin. Resistance of Pseudomonas aeruginosa stains to Cefazolin, Cefuroxime, Cefotaxime, and Cefoxitin were 100% nearly. Resistance of Acinetobacter baumanii stains against Cefazolin, Cefuroxime were 100%. Ciprofloxacin resistance among Escherichia coli isolates increased from 25 to 44.4%. On the contrary, resistance of Enterobacter cloacae stains to Cefotaxime and Ceftazidime were decreased from 83.3 to 36.4%. Conclusions: From 2003 to 2014, positive rate of intraoperative bone culture of chronic osteomyelitis was decreased; the proportion of Staphylococcus aureus was decreased gradually, and our results indicate the importance of bacterial surveilance studies about chronic osteomyelitis.
- 18 September 2019
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 19 (1) , 1-8
Open AccessBacterial resistance trends among intraoperative bone culture of chronic osteomyelitis in an affiliated hospital of South China for twelve years
Background: The purpose of this study was to gather temporal trends on bacteria epidemiology and resistance of intraoperative bone culture from chronic ostemyelitis at an affiliated hospital in South China. Method: Records of patients with chronic osteomyelitis from 2003 to 2014 were retrospectively reviewed. The medical data were extracted using a unified protocol. Antimicrobial susceptibility testing was carried out by means of a unified protocol using the Kirby-Bauer method, results were analyzed according to Clinical and Laboratory Standards Institute definitions. Result: Four hundred eighteen cases met our inclusion criteria. For pathogen distribution, the top five strains were Staphylococcus aureus (27.9%); Pseudomonas aeruginosa (12.1%); Enterobacter cloacae (9.5%); Acinetobacter baumanii (9.0%) and Escherichia coli (7.8%). Bacterial culture positive rate was decreased significantly among different year-groups. Mutiple bacterial infection rate was 28.1%. One strain of Staphylococcus aureus was resistant to linezolid and vancomycin. Resistance of Pseudomonas aeruginosa stains to Cefazolin, Cefuroxime, Cefotaxime, and Cefoxitin were 100% nearly. Resistance of Acinetobacter baumanii stains against Cefazolin, Cefuroxime were 100%. Ciprofloxacin resistance among Escherichia coli isolates increased from 25 to 44.4%. On the contrary, resistance of Enterobacter cloacae stains to Cefotaxime and Ceftazidime were decreased from 83.3 to 36.4%. Conclusions: From 2003 to 2014, positive rate of intraoperative bone culture of chronic osteomyelitis was decreased; the proportion of Staphylococcus aureus was decreased gradually, and our results indicate the importance of bacterial surveilance studies about chronic osteomyelitis.
- Open Access
- 8 February 2019
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 20 (1) , 1-7
Lengthening of free fibular grafts for reconstruction of the residual leg length discrepancy
We evaluated our results of lengthening of free vascularized fibular grafts using a unilateral external fixator in patients with residual leg length discrepancy after free vascularized fibular graft for lower limb reconstruction. Two patients were administrated to our hospital with residual tibial length discrepancy after vascularized free fibular graft surgery. Lengthening of the free vascularized fibular graft with a unilateral external fixator was performed to correct the leg length discrepancy. Both patients recovered well with no difficult in activities of daily living at the last follow-up. This study shows that lengthening of free vascularized fibular grafts with an external fixator is an effective treatment for massive residual leg shortening after vascularized free fibular graft surgery.
- 8 February 2019
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 20 (1) , 1-7
Open AccessLengthening of free fibular grafts for reconstruction of the residual leg length discrepancy
We evaluated our results of lengthening of free vascularized fibular grafts using a unilateral external fixator in patients with residual leg length discrepancy after free vascularized fibular graft for lower limb reconstruction. Two patients were administrated to our hospital with residual tibial length discrepancy after vascularized free fibular graft surgery. Lengthening of the free vascularized fibular graft with a unilateral external fixator was performed to correct the leg length discrepancy. Both patients recovered well with no difficult in activities of daily living at the last follow-up. This study shows that lengthening of free vascularized fibular grafts with an external fixator is an effective treatment for massive residual leg shortening after vascularized free fibular graft surgery.
- 1 July 2016
- Published by Elsevier in Pathology - Research and Practice
- Vol. 212 (7) , 636-642
The clinical pathological significance of Thy1 and CD49f expression in chondrosarcomas
- 1 July 2016
- Published by Elsevier in Pathology - Research and Practice
- Vol. 212 (7) , 636-642
The clinical pathological significance of Thy1 and CD49f expression in chondrosarcomas
- Open Access
- 11 May 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (31) , 50805-50813
mTOR: An attractive therapeutic target for osteosarcoma?
Osteosarcoma (OS) is a common primary malignant bone tumor with high morbidity and mortality in children and young adults. How to improve poor prognosis of OS due to resistance to chemotherapy remains a challenge. Recently, growing findings show activation of mammalian target of rapamycin (mTOR), is associated with OS cell growth, proliferation, metastasis. Targeting mTOR may be a promising therapeutic approach for treating OS. This review summarizes the roles of mTOR pathway in OS and present research status of mTOR inhibitors in the context of OS. In addition, we have attempted to discuss how to design a better treatment project for OS by combining mTOR inhibitor with other drugs.
- 11 May 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (31) , 50805-50813
Open AccessmTOR: An attractive therapeutic target for osteosarcoma?
Osteosarcoma (OS) is a common primary malignant bone tumor with high morbidity and mortality in children and young adults. How to improve poor prognosis of OS due to resistance to chemotherapy remains a challenge. Recently, growing findings show activation of mammalian target of rapamycin (mTOR), is associated with OS cell growth, proliferation, metastasis. Targeting mTOR may be a promising therapeutic approach for treating OS. This review summarizes the roles of mTOR pathway in OS and present research status of mTOR inhibitors in the context of OS. In addition, we have attempted to discuss how to design a better treatment project for OS by combining mTOR inhibitor with other drugs.
- 1 October 2015
- Published by Elsevier in International Immunopharmacology
- Vol. 28 (2) , 1084-1090
Multifaceted roles of adiponectin in rheumatoid arthritis
- 1 October 2015
- Published by Elsevier in International Immunopharmacology
- Vol. 28 (2) , 1084-1090
Multifaceted roles of adiponectin in rheumatoid arthritis